Laparoscopic cytoreductive surgery and HIPEC for advanced ovarian cancer

[1] Morton M, Chambers LM, Costales AB, Chichura A, Gruner M, Horowitz MP, et al. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer. Gynecologic Oncology. 2020; 160: 45–50.

[2] Rodríguez-Ortiz L, Arjona-Sánchez A, Ibañez-Rubio M, Sánchez-Hidalgo J, Casado-Adam A, Rufián-Peña S, et al. Laparoscopic cytoreductive surgery and HIPEC: a comparative matched analysis. Surgical Endoscopy. 2020; 35: 1778–1785.

[3] Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. American Journal of Obstetrics and Gynecology. 2008; 199: 642. e1–642.e6.

[4] Chang SJ, Bristow RE, Chi DS, Cliby WA. Role of aggressive surgical cytoreduction in advanced ovarian cancer. Journal of Gynecologic Oncology. 2015 26: 336–342.

[5] Lampe B, Kroll N, Piso P, Forner DM, Mallmann P. Prognostic significance of Sugarbaker’s peritoneal cancer index for the oper-ability of ovarian carcinoma. International Journal of Gynecological Cancer. 2015; 25: 135–144.

[6] Arjona-Sanchez A, Rufian-Peña S, Artiles M, Sánchez-Hidalgo JM, Casado-Adam Á, Cosano A, et al. Residual tumour less than 0.25 centimetres and positive lymph nodes are risk factors for early relapse in recurrent ovarian peritoneal carcinomatosis treated with cytoreductive surgery, HIPEC and systemic chemotherapy. International Journal of Hyperthermia. 2018; 34: 570–577.